Women with intermediate recurrence scores 11—24 were randomly assigned to either endocrine therapy or endocrine therapy plus chemotherapy. Only outcomes for the low recurrence score group have been reported. Other databases have been prospectively evaluated using a number of different assays and support the observation that women with a low-risk multigene assay can safely omit adjuvant systemic chemotherapy.
Other assays have not yet been included in staging, but this does not preclude their use in clinical care as determined by the patient and physician using data existing at the time of treatment. The panel is committed to reevaluating and updating the staging system to include other multigene panels that are being evaluated prospectively in studies, such as MINDACT using the Mammaprint test. As in all prior editions, the 8th edition reports the prognosis of patients offered appropriate treatment.
While the AJCC 8th edition staging system for breast cancer remains based on TNM staging, permitting comparisons with prior years, it incorporates changes in the understanding of the biological diversity of breast cancer appropriate for contemporary and future management.
Molecular portraits of human breast tumours. J Clin Oncol. Article PubMed Google Scholar. Prospective validation of a gene expression assay in breast cancer. N Engl J Med. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group WSG PlanB trial.
Breast Cancer Res Treat. Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry. NPJ Breast Cancer.
Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index BCI assay, gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol. Validation study of the American Joint Committee on cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer.
JAMA Oncol. The AJCC promulgates best staging practices through each new edition in an effort to provide cancer care providers with a powerful, knowledge-based resource for the battle against cancer. In this commentary, the authors highlight the overall organizational and structural changes as well as "what's new" in the Eighth Edition.
It is hoped that this information will provide the reader with a better understanding of the rationale behind the aggregate proposed changes and the exciting developments in the upcoming edition. Organized by disease site into 57 comprehensive chapters, the Seventh Edition features much-anticipated, major revisions to many chapters including breast, colon, prostate, kidney, and others. There are new primary site chapters for extrahepatic bile ducts, distal bile duct, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and the adrenal gland plus a vastly expanded section on ophthalmologic malignancies.
The Seventh Editions of the AJCC Cancer Staging Handbook and Manual remain the essential references for oncologists, pathologists, surgeons, cancer registrars and medical professionals worldwide to ensure that all those taking care of cancer patients are fully versed in the language of cancer staging. Editors : Stephen B. Edge , David R. Sullivan , J. Milburn Jessup , James D. Brierley , Lauri E. Gaspar , Richard L. Schilsky , Charles M. Balch , David P. Winchester , Elliot A. Asare , Martin Madera , Donna M.
Gress , Laura R. Copyright :
0コメント